Autopsy-tissues were obtained from eight patients who had last receive
d menogaril (total cumulative dose, 175-1080 mg/m2) intravenously (one
patient) or orally (seven patients) from 1 to 285 days prior to death
. Tissue samples were assayed for menogaril and its metabolities by hi
gh-pressure liquid chromatography. Unchanged menogaril was found only
in a single lung-tissue sample from a patient who had died <24 h after
receiving his last treatment. N-Demethylmenogaril was found in two lu
ng-tissue samples and in single samples of the thyroid, lymph node, pa
ncreas, cerebellum, and tumor. The major menogaril metabolite found in
human autopsy-tissues was 7-deoxynogarol. The highest 7-deoxynogarol
concentrations were found in the large bowel (median, 201 ng/g), liver
(median, 183 ng/g), and lung (median, 177 ng/g). The heart ranked as
the 9th of 18 organs in median 7-deoxynogarol concentration, after the
large bowel, liver, lung, tumor, thyroid, skeletal muscle, adrenal gl
and, and kidney. The lowest concentrations were detected in brain tiss
ue. Our results suggest that the low degree of cardiac toxicity and th
e possible pulmonary toxicity of menogaril may be related to relative
tissue concentrations of menogaril metabolites. Tumor 7-deoxynogarol c
oncentrations were comparable with those in normal tissues, except tha
t concentrations in intracerebral tumors were higher than those in the
normal brain. Tissue 7-deoxynogarol concentrations appeared to be dir
ectly related to the cumulative dose and inversely related to the time
from the last treatment to death; the value obtained by dividing dose
by time correlated (P < 0.05) with tissue 7-deoxynogarol concentratio
ns.